National Longitudinal Cohort of Hematological Diseases (NICHE) - CART

Launched by INSTITUTE OF HEMATOLOGY & BLOOD DISEASES HOSPITAL, CHINA · Sep 18, 2024

Keywords

ClinConnect Summary

The NICHE-CART trial is studying a type of treatment called CAR-T cell therapy for patients with blood cancers, known as hematological malignancies. This research will gather information from many patients across different hospitals in China to better understand how effective this therapy is in real-world settings. By collecting data from patients who are already receiving CAR-T therapy, the trial aims to create a large group of information that can help improve treatment options for others in the future.

To be eligible for this study, patients must have a confirmed diagnosis of a blood cancer and must have received CAR-T cell therapy. They also need to sign a consent form agreeing to participate. If you or a family member qualify, you can expect to share your treatment experiences and health information, which will help researchers learn more about this therapy's impact. This study is currently looking for participants of all ages and genders, making it an important opportunity for many individuals affected by these conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with clinically diagnosed hematologic malignancies
• • Patients treated with CAR-T cell therapy
• • Signed the informed consent form